袢利尿剂处方与老年心衰患者30天结局
该研究基于 Medicare 链接的 OPTIMIZE-HF 注册数据,纳入 25,345 例因心衰住院的老年患者,其中 9,866 例(39%)入院前未使用利尿剂。排除透析及出院用噻嗪类者后,7,936 例中 5,568 例(70%)出院时获袢利尿剂处方。倾向评分匹配 2,191 对患者,袢利尿剂组 30 天全因死亡风险显著低于未用组(HR 0.73,95%CI 0.57-0.94,P=0.016),30 天心衰再入院风险也显著降低(HR 0.79,95%CI 0.63-0.99,P=0.037),但 60 天随访时关联均无统计学意义。
要点
- 入院前未用利尿剂的老年心衰患者,出院处方袢利尿剂与 30 天全因死亡风险降低相关(HR 0.73)。
- 袢利尿剂组 30 天心衰再入院风险显著降低(HR 0.79),但 30 天全因再入院无显著差异。
- 上述关联在 60 天随访时均无统计学意义,提示获益可能集中于短期。
核心结论
- 因心衰失代偿住院且入院前未用利尿剂的老年患者,出院获袢利尿剂处方者 30 天临床结局显著优于未处方者。
研究设计与样本
- 基于 Medicare 链接的 OPTIMIZE-HF 注册研究,25,345 例因心衰住院的老年患者中 9,866 例(39%)入院前未用利尿剂。
- 排除透析 1,083 例及出院用噻嗪类 847 例后,7,936 例中 5,568 例(70%)出院获袢利尿剂处方。
- 采用倾向评分匹配构建 2,191 对患者队列,平衡 74 项基线特征,匹配队列 n=4,382。
主要发现
- 匹配队列平均年龄 78 岁,女性 54%,非裔美国人 11%。
- 30 天全因死亡在袢利尿剂组为 4.9%(107/2,191),未用组为 6.6%(144/2,191),HR 0.73(95%CI 0.57-0.94,P=0.016)。
- 30 天心衰再入院 HR 0.79(95%CI 0.63-0.99,P=0.037),30 天全因再入院 HR 0.89(95%CI 0.79-1.01,P=0.081)。
- 60 天随访时所有关联均无统计学意义。
临床怎么用
- 对因心衰失代偿住院、入院前未用利尿剂的老年患者,出院时处方袢利尿剂可能改善 30 天死亡与心衰再入院结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Heart failure (HF) is a major source of morbidity and mortality. Fluid retention and shortness of breath are its cardinal manifestations for which loop diuretics are used. Although their usefulness is well accepted, less is known about their role in improving clinical outcomes. OBJECTIVES: The purpose of this study was to determine the relationship between loop diuretics and clinical outcomes in patients with HF. METHODS: Of the 25,345 older patients hospitalized for HF in the Medicare-linked OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) registry, 9,866 (39%) received no pre-admission diuretics. The study excluded 1,083 patients receiving dialysis and 847 discharged on thiazide diuretics. Of the remaining 7,936 patients, 5,568 (70%) were prescribed loop diuretics at discharge. Using propensity scores for receipt of loop diuretics estimated for each of the 7,936 patients, a matched cohort of 2,191 pairs of patients was assembled balanced on 74 baseline characteristics. Hazard ratios (HRs) and 95% confidence intervals (CIs) for outcomes were estimated in the matched cohort. RESULTS: Matched patients (n = 4,382) had a mean age of 78 years, 54% were women, and 11% were African American. The 30-day all-cause mortality occurred in 4.9% (107 of 2,191) and 6.6% (144 of 2,191) of patients in the loop diuretic and no loop diuretic groups, respectively (HR when the use of loop diuretics was compared with nonuse: 0.73; 95% CI: 0.57 to 0.94; p = 0.016). Patients in the loop diuretic group had a significantly lower risk of 30-day HF readmission (HR: 0.79; 95% CI: 0.63 to 0.99; p = 0.037) but not of 30-day all-cause readmission (HR: 0.89; 95% CI: 0.79 to 1.01; p = 0.081). None of the associations was statistically significant during 60 days of follow-up. CONCLUSIONS: Hospitalized older patients not taking diuretics prior to hospitalization for HF decompensation who received a discharge prescription for loop diuretics had significantly better 30-day clinical outcomes than those not discharged on loop diuretics. These findings provide new information about short-term clinical benefits associated with loop diuretic use in HF.
引用
- Faselis C, Arundel C, Patel S, et al. Loop Diuretic Prescription and 30-Day Outcomes in Older Patients With Heart Failure. J Am Coll Cardiol. 2020. PMID: 32762901. doi:10.1016/j.jacc.2020.06.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。